Our major Licensing focus is in our strategic therapeutic areas:

• respiratory diseases
• urology
• cardiovascular diseases
• central nervous system (CNS) disorders
• virology
• metabolic diseases
• immunology
• oncology
• breakthrough innovations in other areas

The Viramune Donation Programme was inaugurated in 2000 as Boehringer Ingelheim's contribution to pMTCT in developing countries. It serves as a catalyst for building health care infrastructure and has the potential to reach out to more remote sites. The programme provides single-dose nevirapine for mother and baby free of charge for pMTCT. Where available, it should be administered with additional anti-retroviral medicine as recommended by WHO. Recent studies suggest that in women and infants previously treated with single-dose nevirapine for prevention of mother-to-child-transmission of HIV-1, the efficacy of subsequent Viramune® combination therapy may be reduced.

To apply for the Viramune® MTCT Donation Programme have a look on this website pMTCT Donation Program Website which is administered by Axios International.

The ultimate parent company of the Boehringer Ingelheim Corporation is C.H. Boehringer Sohn. Boehringer Ingelheim GmbH, which is a subsidiary of C. H. Boehringer Sohn, is the central holding company for administrative purposes - the corporate central body which manages and directs the worldwide family of Boehringer Ingelheim companies and which delivers central services to all companies of the Corporation.

Boehringer Ingelheim GmbH, our Headquarters in Ingelheim/Germany

• is the central holding company for administrative purposes
• manages and directs as corporate central body the worldwide family of Boehringer Ingelheim companies
• is the ultimate parent company of the Boehringer Ingelheim corporation as a subsidiary of C. H. Boehringer

The ultimate parent company of Boehringer Ingelheim is C.H. Boehringer Sohn.

Boehringer Ingelheim has 138 affiliated companies in 47 countries.

You can download a copy of the Annual Report 2008 as a pdf file

" Value through Innovation" is our Corporate vision, our headline goal.

Boehringer Ingelheim traces its history directly back to 1885, when Albert Boehringer set up his chemical factory making tartaric acid salts in Ingelheim, Germany.

There was a separate pharma company called Boehringer Mannheim until 1998, when it was absorbed into the Swiss company Roche. It did indeed spring from the same origins.

In 1817, Christian Friedrich Boehringer helped found a drug store and chemical laboratory in Stuttgart, which his son Christoph Heinrich moved to Mannheim in 1872. When C.H. Boehringer died in 1882, his elder son Ernst inherited the business in Mannheim, which was called C.F. Boehringer & Söhne.

Christoph Heinrich's younger son, Albert Boehringer, then set up his own chemical factory producing tartaric acid salts in Ingelheim in 1885. In 1892, he renamed this business "C.H. Boehringer Sohn" in memory of his father.

In 1892, Ernst Boehringer died, leaving the C.F. Boehringer business in the hands of his partner Dr Friedrich Engelhorn. Thus there were two pharmaceutical businesses bearing similar Boehringer names - one owned by the Boehringer family and one not.

In 2008, the Boehringer Ingelheim group of companies had a total mean of 41,300 employees worldwide.

Our mean total workforce by region in 2008
AAA: 6,300 (+5.2%)
Americas: 13,443 (+2.4%)
Europe (EU): 21,557 (+4.2%), incl. apprentices

Our mean total workforce by function in 2008
Production: 12,600 (30.5%)
Administration: 5,299 (12.8%)
Marketing & Sales: 15,909 (38.5%)
Research & Development: 6,788 (16.4%)

In Biopharmaceuticals the active substances like monoclonal antibodies and other therapeutic proteins are produced by cells and microorganisms, and not through chemical synthesis.

For more than 25 years now, Boehringer Ingelheim has an international reputation as a reliable partner for industrial customer

• as developer and manufacturer of biopharmaceuticals from mammalian cells and microorganisms.

To maintain our strong performance in production of therapeutics derived from bacterial fermentation (Vienna, Austria) our biopharmaceuticals plant was inaugurated in 2005. In 2006, we received the successful validation.

Our Biberach site is the world's second largest plant for biopharmaceutical production of therapeutics derived from mammalian cell cultures, the production capacity has been doubled in 2003 with EUR 255 million investment.

Our Pharmaceuticals Production Division produces Boehringer Ingelheim's own drugs in a globally coordinated production network as well as offering manufacturing services to our industrial customer according to their specific needs

Eight world-class state of the art manufacturing facilities, operated by highly experienced personnel, offer services in three continents. The proven track record of pharmaceuticals development and wide ranges of manufacturing technologies and packaging technologies in combination with the fully harmonised supply chain network offers many possibilities for the success of our customers.

Our Pharma Chemicals Division's core competence is manufacturing, finishing and distributing proprietary and generic active pharmaceutical ingredients (APIs). In addition to synthetic products, it is also the world leader in phytochemicals - extracting active ingredients from medicinal plants.

Pharma Chemicals expertise is in providing all-round integrated solutions to customers across the pharmaceutical industry in addition to meeting Boehringer Ingelheim's own requirements.

Boehringer Ingelheim's continued success is based on solid ground - our own R&D and our partner's excellence. Our alliances range from early stage research to development and marketing or co-promotion collaborations.

Within the Licensing Organisation Boehringer Ingelheim has two dedicated groups for the different functions within a partnering process:

Cross-functional Licensing Advisory Teams
Headed by Licensing Advisory Team Leaders with representatives from R&D, Medicine and Marketing responsible to evaluate opportunities. The Licensing Advisory Team Leaders have broad understanding of respective indication area, dedicated to identify opportunities of potential strategic interest. Immediate involvement of a broad range of disciplines ensures early alignment and rapid decision making within Boehringer Ingelheim.

Our major Licensing focus is in our strategic therapeutic areas:

• respiratory diseases
• urology
• cardiovascular diseases
• central nervous system (CNS) disorders
• virology
• metabolic diseases
• immunology
• oncology
• breakthrough innovations in other areas

Drug discovery, pre-clinical and clinical development take about 12 - 15 years and including failures an investment of in average US$ 1 billion. Every year, Boehringer Ingelheim invests about a fifth of its net sales in Prescription Medicines into research and development. The phases in the process from idea to patient are:

• Basic research and exploratory research
• Research (with target identification, target validation, lead identification, lead optimisation, pre-development )
• Development (with preclinical development, clinical research phases I, II and III)
• Registration (with regulatory approval and phase IV/Life Cycle Management)

Over the past few years we have seen fast-paced developments in the opportunities to explore human genomic codes and its relation to diseases. Knowledge about the genetic structure and principles of the human body opens the door for the identification of new targets for innovative therapies.

Genetic research and modification are understood as opportunities to develop therapies to fight diseases that are so far only hardly treatable or untreatable. Carefully and respectfully approaching these opportunities, Boehringer Ingelheim is interested in research and development in gene therapy.

We encourage genetic research, because we believe that all avenues of progress towards better human and animal health deserve to be explored.

However, we recognise the concerns over the possible long-term consequences of genetic modification and cloning. We are guided by extreme caution in these new and explorative research areas. We strongly adhere to our philosophy that no irreversible modification should be done until is proven to be safe.

Boehringer Ingelheim has a general policy of transparency with publications of clinical trial results. We recognize that there are important public health benefits associated with making clinical trial information more widely available to healthcare professionals and patients. Such disclosure, however, must maintain protections for intellectual property and contract rights as well as conform to the regulations in relevant countries.

Boehringer Ingelheim supports the joint global position of the research-based pharmaceutical industry published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on 06 January 2005, updated on 18 November 2008, and is committed to the agreed principles.
The disclosure process is based upon the requirements outlined in the global industry position paper of the IFPMA, the requirements by the United States Food and Drug Administration Amendments Act of 2007 (FDAAA), and the United States state of Maine law regarding the Reporting Requirements for Pharmaceutical Manufacturers and Labelers for approved products marketed in the state of Maine.

The Accelerating Access Initiative is a cooperative endeavor of seven research-based pharmaceutical companies including Boehringer Ingelheim, UN agencies and the World Bank. The initiative started in 2000 and by June 2006, the treatments delivered by the Accelerating Access Initiative in developing countries were reaching more than 750,000 patients.

The participants of the initiative are committed to working with governments, international organisations and other stakeholders to find ways to broaden access while ensuring rational, effordable, safe and effective use of drugs for HIV/AIDS-related illnesses.

The Viramune Donation Programme was inaugurated in 2000 as Boehringer Ingelheim's contribution to pMTCT in developing countries. It serves as a catalyst for building health care infrastructure and has the potential to reach out to more remote sites. The programme provides single-dose nevirapine for mother and baby free of charge for pMTCT. Where available, it should be administered with additional anti-retroviral medicine as recommended by WHO. Recent studies suggest that in women and infants previously treated with single-dose nevirapine for prevention of mother-to-child-transmission of HIV-1, the efficacy of subsequent Viramune® combination therapy may be reduced.

To apply for the Viramune® MTCT Donation Programme have a look on this website pMTCT Donation Program Website which is administered by Axios International.

To increase access to anti-retrovirals in the developing and emerging economies, Boehringer Ingelheim has also participated in initiatives with other organisations, such as:

• Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)
• AIDS Health Care Foundation (AHF)
• Community Health and Information Network (CHAIN)
• International Federation of Chemical, Energy, Mine and General Workers' Unions (ICEM):
• HIV/AIDS Workplace Programme in India

Furthermore, Boehringer Ingelheim is running different training activities, for example

• the Boehringer Ingelheim Facilitation and Training Centre in Botswana,
• training for health staff in Papua New Guinea,
• technology transfer by training of East African pharmaceutical technicians.

To view a podcast one is required to download the individual podcast or to subscribe to a podcast series.

Please install a podcatcher, a software which is capable of searching the web to find the latest podcast and which automatically delivers it to your computer.

To receive and display RSS feeds, you need a newsreader or aggregator. This is a piece of software that checks RSS feeds and lets you read them. There are two possibilities to access RSS news feeds: online by using a browser or on your desktop with a downloadable application.

RSS via Browser:
Many browsers provide integrated support for RSS feeds. With them you can easily bookmark your favourite news feeds and read it online like a website. A list of various browsers is available at the Google Directory. For more details on these functionality and information about your browser, please check their websites.